<DOC>
	<DOCNO>NCT01345253</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety belimumab addition standard therapy compare placebo subject Northeast Asia systemic lupus erythematosus ( SLE ) 52 week period .</brief_summary>
	<brief_title>GSK1550188 A 52 Week Study Belimumab Versus Placebo Treatment Subjects With Systemic Lupus Erythematosus ( SLE ) Located Northeast Asia</brief_title>
	<detailed_description>The purpose study demonstrate efficacy safety belimumab 10mg/kg administer intravenously ( IV ) every 4 week compare placebo , patient SLE add standard care therapy , measure SLE Responder Index ( SRI ) 52 week , define composite endpoint use SELENA SLEDAI score , Physician 's Global Assessment ( PGA ) BILAG A B organ domain score .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Age 18 year old . Have clinical diagnosis SLE accord American College Rheumatology ( ACR ) classification criterion . Have active SLE disease . Have positive antinuclear antibody ( ANA ) test result . Are stable SLE treatment regimen . Females childbearing age willing use appropriate contraception Have receive treatment B cell target therapy time . Have receive biologic investigational agent past year . Have receive 3 course systemic corticosteroid past year . Have receive intravenous ( IV ) cyclophosphamide within 180 day prior Day 0 . Have severe lupus kidney disease . Have active central nervous system ( CNS ) lupus . Have major organ transplant . Have significant unstable uncontrolled acute chronic disease condition due SLE . Have plan surgical procedure . Cancer within last 5 year , except adequately treated skin cancer , carcinoma situ uterine cervix . Have require management acute chronic infection past 60 day . Have current drug alcohol abuse dependence . Have historically positive test , test positive screening HIV , Hepatitis B , Hepatitis C. Have IgA deficiency . Have severe laboratory Abnormalities . Have anaphylactic reaction Xray contrast agent biologic agent . Suicidal behavior ideation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SLEDAI</keyword>
	<keyword>Asia</keyword>
	<keyword>placebo</keyword>
	<keyword>BLys</keyword>
	<keyword>PGA</keyword>
	<keyword>BILAG</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>SELENA</keyword>
	<keyword>Lupus</keyword>
	<keyword>SRI</keyword>
	<keyword>efficacy</keyword>
	<keyword>B cell</keyword>
	<keyword>SLE Flare Index</keyword>
	<keyword>belimumab</keyword>
	<keyword>safety</keyword>
	<keyword>phase III</keyword>
	<keyword>B lymphocyte</keyword>
</DOC>